OncoSec Medical is a tremendously undervalued company. It has a capitalization of $27MM and a cash flow of $9MM. Besides, it is carrying out several major studies. Immunopulse and Neopulse treatments can provide it with an income of $500MM annually minimum. This enterprise should have a minimum capitalization of $250MM or $2.5 per share.
*Pipeline overview data sourced from OncoSec Medical, all other data sourced from Nasdaq.com, CNN Money as well as the web of the previously mentioned company.